

## CUMULATIVE INDEX 1994

### Volume 14

---

March	BLOOD CULTURES, pages 1-202
June	HIV/AIDS, pages 203-450
September	ALTERNATE-SITE LABORATORY TESTING, pages 451-676
December	THROMBOSIS AND HEMOSTASIS: PART I, pages 677-869

---

Note: Page numbers of article titles are in **boldface** type

- A77003 (protease inhibitor), in HIV infection, 379
- Abbott MS-2 system, for antibiotic susceptibility testing, 177  
for rapid microbial identification, 187
- Abortion, saline-induced, disseminated intravascular coagulation in, 732
- spontaneous, from lupus anticoagulants, 797
- Abuscreen OnTrak, for urine screening, 487
- Accreditation, in alternate-site testing, **605-622**
- College of American Pathologists, 606-607  
checklist for, 475-480, 484, 608-616  
in multihospital systems, 504-505
- Joint Commission on Accreditation of Healthcare Organizations, 607, 616-622
- AccuProbe test, in rapid microorganism detection, 191
- Acidosis, in disseminated intravascular coagulation, 733, 739
- ACL instrument, for coagulation evaluation, 717-718
- Acquired immunodeficiency syndrome. *See Human immunodeficiency virus infection.*
- Acridinium ester probe, in HIV detection, 317
- Actinobacillus actinomycetemcomitans*, blood culture of, 124
- Activated clotting time, in heparin therapy monitoring, 827
- Activated partial thromboplastin time, high phospholipid, in lupus anticoagulants, 799  
in cirrhosis, 772
- in disseminated intravascular coagulation, 743
- in factor VIII inhibitor disorders, 804
- in heparin therapy monitoring, 827-830
- in hirudin therapy monitoring, 833-834
- in lupus anticoagulants, 798
- measurement of, automated instruments for, 710-715
- phosphatidylserine liposome, in lupus anticoagulants, 799
- Adenoviruses, in gene therapy, for HIV infection, 380-381
- Agar, for blood cultures, 55
- Agar dilution method, for antibiotic susceptibility testing, 175
- Agar slant, in biphasic blood cultures, 136-137
- Agarose gel method, for factor VIII inhibitor screening, 805
- Agglutination tests, for rapid microbial identification, 187-188
- Aging, lead poisoning in, 438-439
- Agnogenic myeloid metaplasia, disseminated intravascular coagulation in, 733
- AIDS. *See Human immunodeficiency virus infection.*
- Air, lead release into, 425  
testing of, for lead, 660
- Alcohol ingestion, lead poisoning in, 438
- Alkalosis, disseminated intravascular coagulation in, 733
- Alpha-2-antiplasmin, action of, 694

- Alpha-2-antiplasmin (*Continued*)  
 deficiency of, in cirrhosis, 772  
 in disseminated intravascular coagulation, 747-748
- Alternate-site testing. *See also Bedside testing.*  
 accreditation in, 475-480, 484, 605-622  
 in multihospital system, 504-505  
 advantages of, 553, 628  
 background of, 451-458  
 historical aspects of, 451-453  
 nomenclature, 453-456  
 professional organization position, 456-458  
 biosensor technology for, 459-471  
 calibration in, 593  
 central laboratory representative in, 572-573  
 clinician vs. laboratorian view of, 452  
 common tests performed in, 587  
 communication in, 559-567  
 competency testing requirements in, 597  
 consolidation in multihospital systems, 493-524  
 accreditation in, 504-505  
 chief of pathology and laboratory medicine role in, 499  
 CLIA impact on, 507-508  
 committee for, 499, 510-513  
 coordinator in, 499-501  
 costs of, regulation-related, 506  
 example of, 501-503  
 glucose testing device guidelines, 513-516  
 history of, 494-495  
 patient outcome and, 505-506  
 personnel for, 517-518  
 proficiency testing in, 503-504  
 rationale for, 495-498  
 regulation enforcement in, 505  
 sites included in, 498  
 test management in, 516-517  
 Veterans Health Administration procedures for, 508-524  
 data base design for, 563  
 definition of, 454-455, 624  
 disadvantages of, 553, 628-629  
 domains of, 454-456  
 economic aspects of, 453, 570-571  
 consolidation in multihospital systems, 506  
 in glucose determination, 485-486  
 quality control and, 541-542  
 errors in, detection of, 495-497  
 potential for, 543-545, 550  
 evolution of, 570-574  
 growth of, 625-626  
 historical aspects of, 451-453  
 in mobile laboratory, 572  
 in patient-centered units, 525-538, 573  
 in satellite laboratory, 571-572  
 in vivo, 456, 468-469, 573-574  
 instrument maintenance in, 595-596  
 interactive multimedia communication networks for, 559-567  
 nomenclature problems in, 453-456  
 patient outcome and, 505-506  
 performance of, survey on, 640-643  
 personnel for, 569-604, 630-636  
 central laboratory representative in, 572-573  
 certification/credentialing of, 585-586  
 clinical consultant, 584-585  
 competency testing of, 597  
 continuing education of, 599-601  
 education of, 577-578, 597-601  
 in multihospital systems, 517-518  
 in patient-centered unit, 526, 528-529, 535-536, 573  
 interest of, 576  
 medical director, 584-585  
 proficiency testing in. *See Proficiency testing.*  
 regulations on, 575, 583-585  
 requirements for, 569-575  
 site-specific considerations in, 586-588  
 technical consultant, 584-585  
 time available to, 576-577  
 training of. *See Training, for alternate-site testing.*  
 vs. central laboratory personnel, 574-575  
 physician-performed microscopy, 583-584  
 politicoeconomic aspects of, 453  
 professional organization position on, 456-458  
 proficiency testing in, 595  
 in multihospital system, 503-504  
 survey on, 637-640  
 quality control/assurance in, 539-557  
 survey on, 633, 637  
 training for, 590-594  
 settings for, 498, 561, 571  
 survey on, 623-645  
 design of, 624  
 results of, 625-629  
 advantages, 628  
 disadvantages, 628-629  
 growth of, 625-626  
 hospital size and, 625  
 length of stay and, 626  
 perceived performance, 640-643  
 persons executing tests, 630-636  
 proficiency, 637-640  
 quality control practices, 633, 637  
 time available for, 576-577  
 training for. *See Training, for alternate-site testing.*  
 vs. hospital size, 625

- vs. length of stay, 626  
vs. monitoring, 588
- Alveolar macrophages, in HIV-specific cytotoxic T lymphocyte detection, 272-273
- Ambulance, biosensor testing in, 462-463
- Aminoglycosides, in HIV infection, 376
- Aminolevulinic acid, measurement of, in lead poisoning, 662
- Aminolevulinic acid dehydrase, inhibition of, in lead poisoning, 649-650
- Aminolevulinic acid synthetase, inhibition of, in lead poisoning, 649-650
- Amniotic fluid embolism, disseminated intravascular coagulation in, 731
- Amplification, of DNA. See *Polymerase chain reaction*.
- Anaerobic bacteremia, 107-117  
blood cultures in, 25, 110-114  
incidence of, 107-108  
microbiology of, 108-110
- Analysts, for alternate-site testing. See *Alternate-site testing, personnel for*.
- Analyzer, portable, 464-465
- Ancillary testing. See *Alternate-site testing*.
- Anemia, in lead poisoning, 649-650
- Anergy, in HIV infection, 229
- Antibiotic(s), removal of, from blood cultures, 40, 75, 140-141
- Antibiotic susceptibility testing, 171-179  
agar dilution method for, 175  
agents for, 171-172  
automated, 176-178  
direct, 173  
disk diffusion method for, 173, 175  
manual methods for, 173-175  
standardized, 172-173
- Antibodies. See also *Circulating anticoagulants*.  
in gene therapy, for HIV infection, 381-382  
in HIV infection, serologic assays for. See under *Serologic assays*.  
to factor IX, laboratory assessment of, 807  
to factor VIII, laboratory assessment of, 803-807
- Anticoagulants (circulating). See *Circulating anticoagulants*.
- Anticoagulants (pharmacologic), in blood cultures, 74-75  
in samples, for reverse transcriptase-polymerase chain reaction, 338
- therapy with, in disseminated intravascular coagulation, 754-755, 758  
monitoring of, 813-823, 825-846  
glycosaminoglycans, 831, 833  
heparin, 826-835  
hirudins, 835-836  
historical background of, 813-815
- international normalized ratios in, 814-815, 817-821
- NO donors, 840
- oral, 813-823
- pentasaccharides, 832
- platelet function inhibitors, 838-839  
reference preparations for, 815-817
- thrombin-inhibiting peptides, 836  
vitamin K antagonists, 837
- Antifibrinolytic agents, in disseminated intravascular coagulation, 756-757  
in liver transplantation, 775
- Antiphospholipid antibodies, laboratory assessment of, 799-801
- Antiplatelet agents, in disseminated intravascular coagulation, 755, 758  
therapy with, monitoring of, 838-839
- Antiretroviral drugs, 367-391  
affecting HIV replication, 368-380  
at CD4 receptor binding step, 370-371  
at cellular penetration step, 372  
at host genome penetration step, 372  
at transcription and translation stage, 373-379  
at viral assembly stage, 379-382  
at viral release stage, 379-382  
efficacy of, monitoring of, 413-414  
polymerase chain reaction in, 327-328, 344-346
- HIV burden response to, 305-308
- HIV resistance to, 393-422  
as pathogenic factor, 408-410  
biochemical bases of, 404-407  
efficacy monitoring in, 413-414  
genetic factors in, 395-399  
in combination therapy, 400-404  
monitoring for, 410-413  
mutations in, 400-404  
replication dynamics and, 394-395  
reverse transcriptase structure and, 404-407
- Antisense oligonucleotides, in HIV infection, 373-374
- Antisense RNA, in HIV infection, 374
- Antiseptics, skin, in blood culture sample collection, 60-61
- Antithrombin, deficiency of, in cirrhosis, 772  
heparin affinity to, 826  
in coagulation regulation, 698-699  
measurement of, chromogenic assay in, 715  
in disseminated intravascular coagulation, 746  
therapeutic, in disseminated intravascular coagulation, 755
- API 20E system, for rapid microbial identification, 186-187
- Apoptosis, of T lymphocytes, in HIV infection, 229-230

- Aprosulate, therapy with, monitoring of, 831
- Arachidonic acid metabolites, in platelet function, 686-687
- Aspergillus*, blood culture of, 93
- Aspirin, in disseminated intravascular coagulation, 758
- therapy with, monitoring of, 838
- Ateviridine, HIV resistance to, 397, 399
- Atherosclerotic plaque, in endothelial injury, 679
- Atomic absorption spectrometry, in lead measurement, 661
- Autobac antibiotic susceptibility testing system, 177-178
- Automation, of antibiotic susceptibility testing, 176-178
- of blood cultures, 65-66, 149-169. See also specific system, e.g., BACTEC systems.
- of coagulation laboratory, 709-728
- instrumentation for, chromogenic assay, 715-720
- clot-based, 711-715
- immunologic assay, 722-725
- platelet, 720-722
- quality control of, 710-711, 725-726
- of microbial identification, 186-187
- 12-Azidododecanoic acid, in HIV infection, 377
- AZT. See *Zidovudine (AZT)*.
- BacT/Alert blood culture system, 161-163
- in anaerobic bactemia, 114
- in brucellosis, 121-122
- BACTEC systems, 150-156, 163-164
- advantages of, 153
- antibiotic removal device for, 140-141
- continuous-monitoring, 157-161, 163-164
- disadvantages of, 153
- for pediatric patients, 23-25
- in anaerobic bactemia, 112-114
- in brucellosis, 120-122
- in *Campylobacter* bactemia, 123
- in fungemia, 85-86, 88
- in mycobacteremia, 101-102
- in mycoplassemia, 126
- in vitamin B<sub>6</sub>-dependent streptococci infection, 127
- nonradiometric, 154-156
- Bacteremia. See also specific organism.
- anaerobic. See *Anaerobic bactemia*.
- breakthrough, 10
- catheter-related, blood cultures in, 51-58
- continuous, 10
- definition of, 2-3
- epidemiology of, 11-13
- intermittent, 10
- microorganisms in, 10-11, 13
- in immunodeficiency, 33
- in pediatric patients, 17-20
- mortality in, 13-15
- nosocomial, in pediatric patients, 30
- polymicrobial, 10
- sources of, 13
- transient, 9-10
- unimicrobial, 10
- Bacteroides*, blood culture of, 108-109
- Bac-T-Screen instrument, for rapid microbial identification, 187
- Beckman CX3 analyzer, 465
- Beckman instruments, for coagulation evaluation, 725
- Bedside testing, 473-491, 627
- biosensors for, 460-462
- blood gases, 487
- casual, 573
- coagulation status, 486
- definition of, 456
- drugs of abuse, 487
- glucose, 474-480
- accuracy of, 477-479
- cost of, 485-486
- devices for, 474-476
- error consequences in, 479-480
- precision of, 476-477
- program components for, 481-485
- quality assurance in, 481-485
- regulation of, 480
- hemoglobin, 487
- multichannel analyzer for, 486-487
- perceived performance of, 643
- personnel for, 632
- proficiency, 639
- program components for, 481-485
- quality assurance in, 481-485
- regulation of, 480
- revenues from, 636
- Benzodiazepines, in HIV infection, 375-376
- Bethesda method, for factor VIII inhibitor assessment, 805-806
- Bile solubility test, for microorganism identification, in blood cultures, 185-186
- Bio Data instruments, for platelet function evaluation, 721
- BioArgos system, 114, 156-157
- Biochemical tests, for microorganism identification, in blood cultures, 184-187
- bioMerieux system, for antibiotic susceptibility testing, 176
- for blood cultures, 165
- for rapid microbial identification, 186-187
- Biosensors, 459-471
- analytes detected by, 461
- clinical settings for, 462-463

- communication system for, 462  
 components of, 460-461  
 definitions of, 460  
 electrochemical, 464-465  
 in bedside testing, 460-462  
     advantages of, 463-464  
 in blood gas monitoring, 466-468  
 in continuous monitoring, *in vivo*, 468-469  
     noninvasive, 466-468  
 in glucose monitoring, 469  
 in near-infrared spectroscopy, 467-468  
 in pulse oximetry, 467  
 performance criteria for, 462  
 prerequisites for, 461-462  
 specimen size for, 461-462  
 test result reporting time for, 462-463  
 transcutaneous, 466-467
- Bio-Tek Instruments, for coagulation evaluation, 725
- Blastomyces dermatitidis*, blood culture of, 93
- Bleeding, from factor VIII inhibitors, 803-804  
     treatment of, 807
- from lupus anticoagulants, 798
- in disseminated intravascular coagulation, 730  
     in diagnosis, 739  
     mechanisms of, 738
- in heparin therapy, 833-834
- in liver disease, 770
- in liver resection, 776
- in liver transplantation, from preexisting coagulopathy, 775
- in vitamin K antagonist therapy, 837
- in von Willebrand's disease, 781-783  
     acquired, 790-791
- Bleeding time, in von Willebrand's disease, 789
- Blood, lead measurement in, 656  
     methods for, 660-662  
     sample collection for, 658-659  
     lead poisoning effects on, 649-650
- Blood cultures, 1-7  
     agitation of, 74  
     anaerobic, 107-117  
         in pediatric patients, 25  
     antibiotic removal from, 75, 140-141  
         in immunocompromised patients, 40  
     antibiotic susceptibility testing in, 171-179
- anticoagulants for, 74-75
- automated, 65-66, 149-169. *See also* specific system, e.g., BACTEC systems.
- in fungemia, 86, 88-89, 91
- BacT/Alert system for, 161-163  
     in anaerobic infection, 114  
     in brucellosis, 121-122
- BACTEC systems for. *See BACTEC systems.*
- BioArgos system for, 114, 156-157  
 biochemical detection methods for, 184-187
- bioMerieux Vital system for, 165
- biphasic, 136-139  
     in anaerobic infection, 112  
     in fungemia, 85-86
- blood-to-broth ratio in, 72-73
- broth displacement system in, 139-140
- broth-based systems for, 133-136
- chromatographic detection methods for, 191
- clinical importance of, 3-4, 9-16
- comparative studies of, critical factors in, 3-6
- contamination of, 11  
     in fungal cultures, 91-92
- continuous-monitoring systems for, 157-166
- cost considerations in, in pediatric patients, 27
- definition of, 2
- Difco ESP system for, 164-165
- direct microscopy in, in catheter-related infections, 53  
     in immunocompromised patients, 40  
     in mycobacteremia, 100-101  
     in pediatric patients, 26
- false-positive, 1-3, 42-43
- fluorescent stains for, in immunocompromised patients, 40
- general principles of, 69-82
- head space atmosphere in, 73
- immunologic detection methods for, 187-191
- in brucellosis, 120-123
- in *Campylobacter* infection, 123-124
- in catheter-related infections, 51-58
- in fungemia, 83-97  
     catheter-related, 51-58  
     in immunocompromised patients, 37-38
- in HACEK bacterial infection, 124
- in immunocompromised patients, 31-49
- in legionellosis, 124-125
- in *Malassezia* infections, 24-25
- in vitamin B<sub>6</sub>-dependent streptococcal infections, 127
- incubation of, 4-5  
     atmosphere for, 111  
     broth-based, 136  
     duration of, 65, 73  
     anaerobic, 111  
     in immunocompromised patients, 41  
         in pediatric patients, 25-26  
     in fungemia, 89-90  
     temperature for, 73-74
- interpretation of, in immunocompromised patients, 42-43

- Blood cultures (Continued)**
- Isolator system for, 24, 142-144
    - in anaerobic bacteremia, 112-113
  - laboratory issues in, in pediatric patients, 23-26
  - lysis-centrifugation system in. See *Lysis-centrifugation system*.
  - manual, 133-147
    - in brucellosis, 122
  - media for. See under *Culture media*.
  - MicroScan system for, 165-166
  - mycobacterial, 99-105
    - in immunocompromised patients, 38-39
    - mycoplasmal, 125-126
    - negative, in immunocompromised patients, 41-42
    - nucleic acids detection methods in, 191
    - number of, 69-70
      - in immunocompromised patients, 35
      - in pediatric patients, 21-22
    - of fastidious microorganisms, 119-131
    - on agar, 55
    - pathogens in, anaerobic, 108-110
      - in immunocompromised patients, 32-33
    - in pediatric patients, 17-20
    - pediatric, 17-30
    - PEDS bottle system for, 24
    - peripheral, in catheter-related infections, 55
      - processing of, 63-66
      - quantitative, in catheter-related infections, 55-56
      - rapid detection and identification methods for, 181-195
        - biochemical, 184-187
        - chromatography in, 191
        - clinical relevance of, 182-184
        - immunologic, 187-191
          - in immunocompromised patients, 41
          - nucleic acids in, 191
        - reporting of, in immunocompromised patients, 42
        - safety in, 127-128
        - semiquantitative, in catheter-related infections, 54-55
        - Septi-Chek system for. See *Septi-Chek system*.
        - signal broth displacement system for, 139-140
        - specimen collection for, 59-68
          - anaerobic, 110
          - in immunocompromised patients, 33-35
          - in pediatric patients, 20-23
          - needle switching in, 62-63
          - skin antisepsis in, 60-61
          - timing of, 60
          - universal precautions in, 61
        - venipuncture vs. catheter specimens in, 61-62
        - specimen transport in, 63
        - subcultures in, 76-78
        - terminology of, 1-3
        - timing of, 70-71
        - true-positive, 2-3, 42-43
        - variables in, 3-6
        - vented bottles in, 135-136
        - viral, in immunocompromised patients, 39-40
        - volume of, 3, 71
          - in fungemia, 89
          - in pediatric patients, 22-23
        - Blood donors, HIV detection in, polymerase chain reaction in, 322
        - Blood gases, measurement of, biosensors in, 466-468
          - sample collection for, 545
        - Blood-to-broth ratio, in blood cultures, 72-73
        - Body fluids, lead measurement in, 657-658
        - Bone, lead measurement in, 657
          - methods for, 662-664
        - Bone marrow, culture of, in immunocompromised patients, 42
          - in pediatric patients, 21
          - lead measurement in, 657
        - Brain, disseminated intravascular coagulation in, 734
          - lead measurement in, 657
        - Brain-heart infusion broth, in fungal blood cultures, 85-86, 88, 91
        - Branch DNA signal amplification, in HIV detection, 337
        - Brucella, blood culture of, 120-123
        - Burns, disseminated intravascular coagulation in, 733-734
        - N-Butyl deoxyxojirimycin, in HIV infection, 376-377

**Caffeic acid phenylethyl ester, in HIV infection**, 372

**Calanolide, HIV resistance to**, 399

**Calibration, in alternate-site testing**, 593

**Campothecin, in HIV infection**, 372

**Campylobacter, blood culture of**, 123-124

**Canadian Society of Clinical Chemists, position on alternate-site testing**, 456-457

**Candida, blood culture of**, 92
 
        - rapid detection of, in blood, 189-190

**Cand-Tec test, for rapid microorganism identification**, 189-190

**Capillary blood, for blood culture**, 21

**Carbon dioxide, monitoring of, biosensors in**, 466-468

**Cardiobacterium hominis, blood culture of**, 124

- Cardiovascular prostheses, disseminated intravascular coagulation from, 734-735
- Cardiovascular system, lead poisoning effects on, 652
- Cartridge, of multichannel analyzer, 464-465
- Castanospermine, in HIV infection, 376
- Catheters, blood culture sampling from, in catheter-related infections, 55-56 in immunocompromised patients, 33-34 in pediatric patients, 20-21 vs. venipuncture, 61-62
- infections related to, blood cultures in, 51-58
- Cavernous hemangioma, giant, disseminated intravascular coagulation in, 734
- Central nervous system, lead poisoning effects on, 650-651
- Cerebrospinal fluid, HIV in, 340
- Certification, of analysts for alternate-site testing, 585-586
- Chelation provocation test, in lead poisoning, 659-660, 663-664
- Chelation therapy, in lead poisoning, 655
- Chemotherapy, blood-borne infection in, 32
- Chloride determination, in portable analyzer, 486
- Chondroitin sulfate, in coagulation regulation, 701-702
- therapy with, monitoring of, 833
- Chromatography, in rapid microorganism detection, in blood, 191
- Chromium, radioactive, in T-lymphocyte cytotoxicity assay, 277
- Chromogenic assay instrumentation, for coagulation evaluation, 715-720
- Chronolog instruments, for platelet function evaluation, 721
- Ciba Corning instruments, for coagulation evaluation, 486, 714-715
- Circulating anticoagulants, 795-812
- coagulation factor inhibitors, 803-808
- factor IX inhibitors, 807
- factor VIII inhibitors, 803-807
- fibrinogen degradation products. See under *Fibrinogen*.
- fibrinogen inhibitors, 807
- heparinlike paraproteins, 802
- in acquired von Willebrand's disease, 808
- lupus, 795-801
- paraprotein inhibitors, 801
- pharmacologic agents, 802-803
- Cirrhosis, of liver, coagulopathies in, 771-773
- CLIA. See *Clinical Laboratory Improvement Amendments*.
- Clinical Laboratory Improvement Amendments, impact of, 494-495, 506
- on quality management, 550-552
- regulations of, alternate-site testing and, 607
- for personnel, 584-585
- vs. Veterans Affairs procedure, 507-508
- test complexity categories of, 583-584
- Clostridia, blood culture of, 109
- Clot formation, automated instrumentation based on, 711-715
- Clot Signature Analyzer, for coagulation evaluation, 715
- COAG-1 device, 486
- Coag-a-Mate instruments, for coagulation evaluation, 712
- Coagglutination tests, for rapid microbial identification, 187-188
- Coagulase test, for microorganism identification, in blood cultures, 185
- Coagulation assay, phospholipid-dependent, for lupus anticoagulants, 798
- Coagulation factors, 691-692. See also under *Factor*.
- assays for, in disseminated intravascular coagulation, 743
- deficiency of, in cirrhosis, 771-772
- inhibitors of, laboratory assessment of, 807-808
- replacement of, in disseminated intravascular coagulation, 755-756
- Coagulation system, disorders of, 795-812
- circulating anticoagulants in, 795-812
- in disseminated intravascular coagulation. See *Disseminated intravascular coagulation*.
- in liver disease. See *Liver disease, coagulopathies of*.
- evaluation of, automated instrumentation for, 709-728
- chromogenic assay, 715-720
- clot-based, 711-715
- immunologic assay, 722-725
- platelet, 720-722
- quality control of, 710-711, 725-726
- bedside, 486
- in disseminated intravascular coagulation, global tests in, 742-745
- molecular markers in, 745-750
- inhibitors of, 698-699
- pathways of, 689-692
- proteins of, coagulation factors, 689-691
- fibrin, 691-692
- thrombin, 691
- regulation of, 698-699
- defects of, in cirrhosis, 772-773
- Coagulometers, in oral anticoagulation monitoring, 819-820

- Cobasbact antibiotic susceptibility testing system, 177
- Coccidioides immitis*, blood culture of, 93
- Colic, lead, 652
- Collagen-induced aggregation test, in antiplatelet agent therapy monitoring, 838-839
- Collagen-vascular disease, disseminated intravascular coagulation in, 734
- College of American Pathologists, accreditation for alternate-site testing, checklist for, 475-480, 484, 608-616 position on alternate-site testing, 457 Q-Probes Study, 475-480, 482, 484 quality control testing requirements of, 482
- Communication, in alternate-site testing, 559-567
- Competency testing requirements, in alternate-site testing, 597
- Complement system, activation of, 695-696
- Complete blood count, in lead poisoning, 660-661
- Computer system, for communication in alternate-site testing, 559-567
- Constipation, in lead poisoning, 652
- Consumptive coagulopathy. See *Disseminated intravascular coagulation*.
- Contaminants, in blood cultures, 11 fungal, 91-92
- Continuous-monitoring blood culture systems, 157-166
- BacT/Alert, 161-163
- BACTEC, 157-161, 163-164
- bioMerieux Vital, 165
- Difco ESP, 164-165
- MicroScan, 165-166
- Corticosteroids, in disseminated intravascular coagulation, thrombogenic effects of, 741-742
- Coulter instruments, for coagulation evaluation, 717-718 for platelet function evaluation, 721
- Coumarin, side effects of, 837
- Coumatria instruments, for coagulation evaluation, 486, 714-715
- Counterimmunolectrophoresis, for rapid microbial identification, 187
- Credentialing, of analysts for alternate-site testing, 585-586
- Critical values, in alternate-site testing, 594
- Cross-training, of personnel, in patient-centered unit, 526, 528-529, 535-536
- Cryptococcosis, antigen detection in, 190 blood culture in, 92
- CTS instrument, for coagulation evaluation, 717
- Culture media, for blood cultures, 71-72 biphasic, 135-137 hypertonic, 24, 76
- in anaerobic bacteremia, 110 in BACTEC systems, 151, 153, 155
- in BioArgos system, 156
- in brucellosis, 122
- in *Campylobacter* bacteremia, 123 in fungemia, 85-86, 88, 90-91 in mycobacteremia, 101-102 in mycoplassemia, 126 in pediatric patients, 23-25 in vitamin B<sub>6</sub>-dependent streptococcal infections, 127
- manual systems, 133-135
- for *Legionella*, 124-125
- Cyclic adenosine monophosphate, in platelet interaction, 685-686
- Cytokines, from cytotoxic T lymphocytes, in HIV infection pathogenesis, 287
- Cytomegalovirus infection, blood culture in, 39-40 disseminated intravascular coagulation in, 733
- Cytotoxic T lymphocytes. See under *T lymphocytes*.
- Data base, for laboratory testing information, 563
- Dataclot instruments, for coagulation evaluation, 714
- ddC. See *Zalcitabine (ddC)*.
- ddI. See *Didanosine (dideoxyinosine, ddI)*.
- D-dimer assay, in disseminated intravascular coagulation, 744
- Decentralized testing. See *Alternate-site testing*.
- Defibrillation syndrome. See *Disseminated intravascular coagulation*.
- Defibrotide, in disseminated intravascular coagulation, 755
- Delavirdine, HIV resistance to, 397, 399
- Dementia, AIDS, cytotoxic T lymphocytes in, 286-287
- Densitometry, in von Willebrand factor multimer assessment, 786
- Deoxynojirimycin, in HIV infection, 376
- Dermatan sulfate, in coagulation regulation, 701-702
- therapy with, monitoring of, 833
- Desmopressin, in von Willebrand's disease, 791
- Detector device, in biosensor, 460-461
- Diagnostica Stago instruments, for coagulation evaluation, 719-720
- DIC. See *Disseminated intravascular coagulation*.
- Didanosine (dideoxyinosine, ddI), HIV resistance to, 396, 398 as pathogenic factor, 408-409 biochemical bases of, 406-407

- in combination therapy, 400  
laboratory monitoring of, 411  
in HIV infection, monitoring of, polymerase chain reaction in, 327  
virus burden response to, 305-306
- Dideoxyguanosine, HIV resistance to, biochemical bases of, 406
- Difco ESP system, for blood cultures, 164-165
- Dilute partial thromboplastin time, in lupus anticoagulants, 798
- Dipyridamole, in disseminated intravascular coagulation, 758
- Directigen test, for rapid microbial identification, 188
- Disk diffusion method, for antibiotic susceptibility testing, 173, 175
- Disseminated intravascular coagulation, 729-768  
compensated, 739  
treatment of, 757-758  
controversy on, 729  
definition of, 730  
diagnosis of, clinical, 739-740  
laboratory, 742-750, 802  
global coagulation tests in, 742-745  
molecular markers in, 745-750  
severity scoring system for, 750-752  
etiology of, 731-735  
vs. treatment options, 752-753  
fulminant, treatment of, 752-757  
historical perspectives of, 731  
in liver disease, 772-773  
in obstetrical accidents, 731-732  
in pregnancy, 731-732  
low-grade, treatment of, 757-758  
monitoring in, 759  
morphologic findings in, 740-742  
pathophysiology of, 735, 737-739  
scoring system for, in diagnosis, 750-752  
in treatment, 758-759  
severity of, assessment of, 750-752  
spectrum of, 730  
terminology of, 730  
treatment of, 752-759
- DNA probes, in rapid microorganism detection, 191
- Drugs, abuse of, urine screening in, portable device for, 487
- antiretroviral. See *Antiretroviral drugs*.
- antithrombotic. See *Anticoagulants (pharmacologic)*.  
lead interaction with, 438
- Dynatech instruments, for coagulation evaluation, 725
- EBP-1, in HIV gene transcription, 244
- Eclampsia, disseminated intravascular coagulation in, 731-732
- Economic aspects, of alternate-site testing, 453, 570-571  
consolidation in multihospital systems, 506  
in glucose determination, 485-486  
quality control and, 541-542
- Education. See also *Training*.  
for alternate-site testing, 577-578, 597-601  
continuing, 599-602
- Eikenella corrodens*, blood culture of, 124
- Elderly persons, blood cultures in, pediatric systems for, 65  
immunosuppression in, blood-borne infection in, 33  
lead poisoning in, 438-439
- Electra instruments, for coagulation evaluation, 712, 719
- Electrochemical biosensors, 464-465
- Electrophoresis, in Western blot test, for HIV, 261
- ELISA. See *Enzyme-linked immunosorbent assay*.
- Embolism, amniotic fluid, disseminated intravascular coagulation in, 731
- Embolization, of esophageal varices, coagulopathies in, 776-777
- Emergency care, testing in, 627  
biosensors in, 462-463, 465  
perceived performance of, 641  
personnel for, 631  
proficiency, 637  
revenues from, 634
- Encephalopathy, lead, 650-651
- Endothelium, vascular, in hemostasis, 678-680  
injury of, disseminated intravascular coagulation in, 735
- Endotoxin, disseminated intravascular coagulation from, 733
- env* gene and gene product, 204-206, 243  
cytotoxic T lymphocytes recognizing, 283-284
- Environmental samples, for lead measurement, 660
- Enzyme-linked immunosorbent assay, for coagulation evaluation, 723-725  
for fibrinopeptides, in disseminated intravascular coagulation, 747  
for HIV antibodies, 258-260  
for plasmin complexes, in disseminated intravascular coagulation, 748
- Epsilon-aminocaproic acid, in disseminated intravascular coagulation, 757
- Erythrocyte(s), lead poisoning effects on, 649-650
- Erythrocyte protoporphyrin, measurement of, in lead poisoning, 661-662
- Esophageal varices, embolization of, coagulopathies in, 776-777

- ESP system, for blood cultures, in fungemia, 88-89
- Ethanol gelation test, for fibrinogen degradation products, 802
- in disseminated intravascular coagulation, 743-744
- Euglobin lysis time, in cirrhosis, 772
- Expiration dates, of reagents, 593-594
- FACSCAN instrument, for platelet function evaluation, 721
- FACTSTAR instrument, for platelet function evaluation, 721
- Factor II, deficiency of, in cirrhosis, 771  
inhibitors of, laboratory assessment of, 807-808
- Factor V, deficiency of, in cirrhosis, 772  
inhibitors of, laboratory assessment of, 807-808
- Factor VII, deficiency of, in cirrhosis, 771  
inhibitors of, laboratory assessment of, 807-808
- Factor VIII, antigen of, assay for, in von Willebrand's disease, 782  
assay for, in von Willebrand's disease, 782  
infusion with, disappearance assay for, in factor VIII inhibitor disorders, 805  
inhibitors of, laboratory assessment of, 803-807  
replacement of, in von Willebrand's disease, 791  
von Willebrand factor binding to, 789
- Factor IX, deficiency of, in cirrhosis, 771  
inhibitors of, laboratory assessment of, 807
- Factor IXa, formation of, 689-690
- Factor X, deficiency of, in cirrhosis, 771
- Factor Xa, formation of, 690-691
- Factor XI inhibitors, laboratory assessment of, 808
- Factor XIII inhibitors, laboratory assessment of, 807-808
- Fastidious microorganisms, blood culture for, 119-131  
*Brucella*, 120-123  
*Campylobacter*, 123-124  
HACEK bacteria, 124  
*Legionella*, 124-125  
*Mycoplasma*, 125-126  
safety issues in, 127-128  
vitamin B<sub>12</sub>-dependent streptococci, 127
- Ferrochelatase, inhibition of, in lead poisoning, 650
- Fetus, lead measurement in, 658  
lead poisoning in, 653  
retained, disseminated intravascular coagulation in, 731
- Fever, in disseminated intravascular coagulation, 739
- Fiberoptics, in intravascular monitoring, 709
- Fibrin(ogen), abnormal, in liver disease, 770-772  
deficiency of, in cirrhosis, 772  
degradation products of, 695, 699  
in disseminated intravascular coagulation, 737-738, 743-745  
laboratory assessment of, 801-802  
deposition of, in disseminated intravascular coagulation, 735, 737, 740  
formation of, 691-692  
inhibitors of, laboratory assessment of, 807
- Fibrinolysis, heparin in, 833
- Fibrinolytic system, 692-695  
activation of, in liver transplantation, 775  
in peritoneovenous shunt installation, 776  
assays for, in disseminated intravascular coagulation, 747-748  
defects of, in cirrhosis, 772-773  
inhibitors of, 694  
in disseminated intravascular coagulation treatment, 756-757
- Fibrinopeptides, elevated, in liver disease, 773  
measurement of, in disseminated intravascular coagulation, 746-747
- Fibrometer instrument, for coagulation evaluation, 712-714
- Fibronectin, 700-701
- Floor testing, 627  
perceived performance of, 643  
personnel for, 633  
proficiency, 640  
revenues from, 636
- Flow cytometry, in platelet function evaluation, 720-722
- Flow Laboratories instruments, for coagulation evaluation, 725
- Fluorescent stains, for blood culture, 40
- Food, lead concentrations in, 427
- Foscarnet, HIV resistance to, 396
- Free erythrocyte protoporphyrin, vs. zinc protoporphyrin, 654
- Fungemia, 83-97  
blood cultures in, catheter-related, 51-58  
evolution of, 85-89  
in immunocompromised patients, 36-38  
variables in, 89-92  
epidemiology of, 11-13  
mortality in, 13-15  
rapid organism identification in, 189-191  
significance of, 83-84  
sources of, 13

- Gabexate, in disseminated intravascular coagulation, 755
- gag* gene and gene product, 204-206, 211
- cytotoxic T lymphocytes recognizing, 278-279
- Gas-liquid chromatography, in rapid microorganism detection, 191
- Gastrointestinal system, lead poisoning effects on, 652
- Gelation tests, in disseminated intravascular coagulation, 743-744
- GEM 91, in HIV infection, 374
- GEM Premier blood gas tester, 487
- Gene therapy, for HIV infection, 380-382
- Genetic factors, in von Willebrand's disease, 789-790
- Genotypic assays, for HIV drug resistance, 410-411
- Giant cavernous hemangioma, disseminated intravascular coagulation in, 734
- Glucose determination, bedside, 474-480
- accuracy of, 477-479
- cost of, 485-486
- devices for, 474-476
- error consequences in, 479-480
- precision of, 476-477
- program components for, 481-485
- quality assurance in, 481-485
- regulation of, 480
- biosensors in, 464-465, 469
- in alternate sites, guidelines for, 513-516
- protocol for, 521-522
- preanalytical errors in, 545
- Glucose oxidase, in glucose monitoring devices, 475
- Glycoproteins, platelet, 687-688
- inhibitors of, therapeutic monitoring of, 839
- Glycosaminoglycan therapy, monitoring of, 831
- synthetic compounds, 831
- Glycosylation, in HIV replication, inhibitors of, 376-377
- Gout, with lead poisoning, 424
- Gram-negative bacilli, anaerobic, blood culture of, 108-109
- Gram-positive bacilli, anaerobic, blood culture of, 109
- Gram-positive cocci, anaerobic, blood culture of, 110
- Granulocytopenia, blood-borne infection in, 32
- HACEK bacteremia, blood culture in, 124
- Haemophilus*, blood culture of, 124
- Hair, lead measurement in, 657
- Helena Laboratories instruments, for platelet function evaluation, 721
- Hemangioma, giant, disseminated intravascular coagulation in, 734
- Hematocrit determination, in portable analyzer, 486
- Hematologic disorders, disseminated intravascular coagulation in, 733
- Hematopoietic system, lead poisoning effects on, 649-650
- Hemochron instrument, for coagulation evaluation, 714
- Hemocue device, 487
- Hemoglobin determination, portable device for, 487
- Hemolysis, intravascular, disseminated intravascular coagulation in, 732
- Hemolytic-uremic syndrome, vs. disseminated intravascular coagulation, 734
- Hemophilia, factor VIII inhibitors in, 803
- Hemostasis. See also *Coagulation system*.
- definition of, 677
- in disseminated intravascular coagulation. See *Disseminated intravascular coagulation*.
- in liver disease. See *Liver disease, coagulopathies of*.
- in von Willebrand's disease, 781-794
- physiology of, 677-707
- compartments involved in, 677
- fibronectin in, 700-701
- plasma protein function in, 688-699
- coagulation system, 689-692
- complement activation, 695-696
- fibrin, 691-692
- fibrinolytic system, 692-695
- inhibitor systems, 698-699
- kinin generation, 697-698
- thrombin, 691
- platelet function in, 681-688
- proteoglycans in, 701-702
- vascular function in, 678-680
- Heparan sulfate, in coagulation regulation, 701-702
- therapy with, monitoring of, 833
- Heparin, activity of, 826
- anticoagulant vs. antithrombotic, 832
- antithrombin III affinity of, 826
- in coagulation regulation, 701-702
- in fibrinolysis, 833
- low-dose, 826
- measurement of, 802-803
- in plasma, 827
- side effects of, monitoring for, 833-835
- therapy with, in disseminated intravascular coagulation, 752, 754-755, 758
- monitoring of, 826-835
- high molecular weight, 826-827, 829
- low molecular weight, 826-830
- unfractionated, 826

- Heparin (Continued)
- very low molecular weight, 832
  - thrombocytopenia from, 834-835
- Heparinlike molecules, laboratory assessment of, 802
- therapy with, monitoring of, 832
- Hepatic artery, thrombosis of, in liver transplantation, 776
- Hepatitis, coagulopathy in, 770-771
- disseminated intravascular coagulation in, 733
- Hepcon instruments, for coagulation evaluation, 714
- HEPT compounds, HIV resistance to, 397, 399
- Heptest, in heparin therapy monitoring, 827-828
- Hereditary hemorrhagic telangiectasia, disseminated intravascular coagulation in, 734
- Hewlett-Packard instruments, for coagulation evaluation, 725
- Hexagonal phospholipid neutralization test, in lupus anticoagulants, 798-799
- High molecular weight fibrinogen complexes, in liver disease, 773
- High-pressure liquid chromatography, in rapid microorganism detection, 191
- Hirudin, in disseminated intravascular coagulation, 755
- therapy with, monitoring of, 835-836
- Histoplasma capsulatum*, blood culture of, 155
- HIV. See *Human immunodeficiency virus*.
- HIV infection. See *Human immunodeficiency virus infection*.
- HIVEN 86A, in HIV gene transcription, 244
- Human immunodeficiency virus (type 1), ancillary proteins of, 212-216
- antibodies to, serologic assays for, 257-269
- assays for, 307-308
- in burden determination, 305
  - clinical management and, 307-308
  - clinical trial design and, 306-307
  - in latent period, 240-242
  - polymerase chain reaction in, 325-328
  - in situ polymerase chain reaction in, 240-241, 351-365
  - polymerase chain reaction in, 313-333
  - reverse transcriptase-polymerase chain reaction in, 335-349
  - serologic, 257-269
  - burden of, 301-311
  - drug resistance and, 394-395
  - measurement of, 305
- clinical management and, 307-308
- clinical trial design and, 306-307
- in latent period, 240-242
- polymerase chain reaction in, 325-328
- phenotype significance in, 304-305
- vs. antiretroviral therapy response, 305-306
- vs. disease progression, 302-305
- cells infected by, 205, 207
- drug resistant. See *Antiretroviral drugs*.
- HIV resistance to*.
- escape of, from cytotoxic T lymphocyte recognition, 287-290
- genes of, 205
- expression of, latency and, 242-246
  - regulation of, 208-211
  - virus burden and, 303
- genomic organization of, 204-205
- latency and, 242-246
- in body fluids, 340-341
- life cycle of, 203-204
- long terminal repeat of, 204, 208-210, 243-244
- molecular biology of, 203-220
- phenotype of, vs. disease progression, 304-305
- progression of, vs. virus burden, 302-305
- provirus of, 240-241, 246-248
- replication of, 211-212
- modes of, 302
  - stages of, drugs affecting, 368-380
- reverse transcription of, 207-208
- strains of, vs. T-lymphocyte depletion kinetics, 232-234
- tissue dissemination of, polymerase chain reaction studies of, 324
- variation of, escape from T-lymphocyte recognition and, 288-289
- vs. type 2, polymerase chain reaction differentiation of, 324
- Human immunodeficiency virus (type 2), genes of, 205-206
- polymerase chain reaction identification of, 324
- Western blot test for, 261-262
- Human immunodeficiency virus infection, asymptomatic. See also subhead: *latency in*.
- polymerase chain reaction in, 321-326
- serologic assays in, 263-264
  - blood culture in, for HIV, 39
  - blood-borne infection in, 33, 36
  - diagnosis of, polymerase chain reaction in, 316-319
  - disseminated intravascular coagulation in, 733
- early events in, 205, 207-208

- in pediatric patients, cytotoxic T lymphocyte function in, 285-286
- polymerase chain reaction detection of, 323
- latency in, 239-255. See also subhead: *asymptomatic*.
- evidence for, 240-242
- genome structure contribution to, 242-246
- host factors in, 246-248
- lupus anticoagulants in, 798
- mathematical model of, 234
- mycobacteremia in, 99-103
- natural history of, neutralizing antibodies in, 264-266
- pathogenesis of, cytotoxic T lymphocytes in, 286-287
- drug resistance and, 408-410
- polymerase chain reaction studies of, 324-327
- seroconversion in, polymerase chain reaction detection before, 321-323
- T lymphocytes in. See under *T lymphocytes*.
- treatment of. See also *Antiretroviral drugs*.
- gene therapy in, 380-382
- polymerase chain reaction monitoring of, 327-328
- virus burden response to, 305-306
- vs. virus burden, 305-308
- vaccines for, cytotoxic T lymphocytes induced by, 290-292
- viremia in, vs. disease progression, 303-304
- virus burden in. See *Human immunodeficiency virus (type 1), burden of*.
- Human leukocyte antigens, on cytotoxic T lymphocytes, HIV-specific, 274-275
- Hyaline microthrombi, in disseminated intravascular coagulation, 741
- Hyaluronic acid, in coagulation regulation, 701-702
- Hypercoagulability, lupus anticoagulants in, 797
- Hypercine, in HIV infection, 372
- Hypersensitivity, to heparin, 835
- Hypertension, in lead poisoning, 652
- Hypertonic media, for blood cultures, 24, 76
- Hypotension, in disseminated intravascular coagulation, 739
- Hypoxia, in disseminated intravascular coagulation, 739
- Immunization, intracellular, in HIV infection, 380-382
- Immunoadhesins, CD4, antiretroviral activity of, 371
- Immunocapture reverse transcriptase test, for HIV, 263
- Immunocompromised patients. See also *Human immunodeficiency virus infection*.
- blood cultures in, 31-49
- antibiotic effect in, elimination of, 40
- fluorescent stains for, 40
- fungal, 37-38
- historical aspects of, 31-32
- incubation of, duration of, 41
- interpretation of, 42-43
- mycobacterial, 38-39
- negative, 41-42
- pathogens in, 32-33
- rapid detection and identification methods for, 41
- rationale for, 31-32
- reporting of, 42
- specimen collection for, 33-35
- systems for, 35-40
- viral, 39-40
- Immunofluorescence assay, for HIV antibodies, 258-259
- Immunologic methods, for coagulation evaluation, 722-725
- for rapid microbial identification, 187-191
- Immunomodulation, HIV in, 225-228
- In situ polymerase chain reaction, in HIV detection, 351-365
- in latent period, 240-241
- in replication studies, 356
- percentage of cell infected, 356-357, 359-362
- sensitivity of, 357-358
- techniques for, 352-355
- In vivo testing, 456, 573-574
- biosensors in, 468-469
- definition of, 456
- Incubation, of blood cultures. See under *Blood cultures*.
- Infection, disseminated intravascular coagulation in, 732-733
- Instrument maintenance, in alternate-site testing, 595-596
- Integrase inhibitors, in HIV infection, 372
- Intensive care unit, testing in, 627
- biosensors in, 463-464
- perceived performance of, 641
- personnel for, 631
- proficiency, 638
- revenues from, 634
- vs. monitoring, 588
- Interferons, in HIV infection, 376, 379-380
- from cytotoxic T lymphocytes, 287
- International normalized ratio, in oral anticoagulation monitoring, 814-815, 817-821
- International sensitivity index, in oral anticoagulation monitoring, 814-820

- International Technidyne instruments, for platelet function evaluation, 721
- Intracellular immunization, in HIV infection, 380-382
- Intravascular monitoring, biosensors for, 468
- Ion-selective electrode, in alternate-site testing, 464-465, 486
- Iron metabolism, lead poisoning and, 437
- Isolator system, for blood cultures, 142-144
- in anaerobic bactemia, 112-113
- in pediatric patients, 24
- i-STAT analyzer, 464-465, 486
- Joint Commission on Accreditation of Healthcare Organizations, accreditation guidelines, in alternate-site testing, 607, 616-622
- manual for all-site testing, 480
- requirements of, 520, 585-586
- quality control testing, 482
- Kallikrein, formation of, 697-698
- Kaolin clotting time test, in lupus anticoagulants, 798-799
- Kaposi's sarcoma, interferon alpha for, 379-380
- Kasabach-Merritt syndrome, disseminated intravascular coagulation in, 734
- Kidney, lead poisoning effects on, 652
- Kingella kingae*, blood culture of, 124
- Kinins, generation of, in disseminated intravascular coagulation, 738
- in hemostasis, 697-698
- Koagulab instruments, for coagulation evaluation, 712
- L697,661 (antiretroviral drug), HIV resistance to, 394, 397, 399
- as pathogenic factor, 408
- Lactation, lead poisoning in, 439
- Langerhans cells, HIV in, 341
- Latency, in HIV infection, 239-255, 263-264, 321-326
- Latex agglutination assay, for coagulation evaluation, 724
- for rapid microbial identification, 187-188
- Laurell method, for coagulation evaluation, 723-724
- LCS system, for fungal cultures, 85-86, 88, 90
- "Lead lines," in lead poisoning, 663
- Lead poisoning, 423-444, 649-668
- aging and, 438-439
- alcohol ingestion and, 438
- blood lead levels in, interpretation of, 655-656
- body burden of, vs. toxicity, 653-656
- cardiovascular effects of, 652
- central nervous system effects of, 650-651
- control of, 430-431, 433-434
- definition of, blood levels in, 424-425
- drug interactions in, 438
- environmental contamination and, 425-427
- from environmental exposure, 431-434
- from increased tissue lead mobilization, 439
- from occupational exposure, 428, 430-431
- from paint, 424-425, 427
- from recreational activities, 434
- from substance abuse, 434-435
- gastrointestinal effects of, 652
- hematopoietic effects of, 649-650
- historical background of, 423-424
- in developing nations, 427-428
- in fetus, 653
- in pediatric patients, 427, 431-434
- blood lead level interpretation in, 655-656
- body burden of, 655
- central nervous system effects in, 651
- newborn, 653
- in pregnancy, 653
- iron interactions in, 437
- lead absorption in, 435-436
- pandemics of, 423-424
- renal effects of, 652
- reproductive effects of, 653
- sources of, 428
- testing in, methods for, 660-664
- protoporphyrins in, 654-655
- quality control in, 664
- sample collection for, 658-660
- specimens for, 656-658
- toxicokinetics of, 436-437
- trace mineral interactions in, 438
- treatment of, in children, 655
- vitamin D metabolism and, 438
- Leader binding protein-1, in HIV gene transcription, 245
- Legionella*, blood culture of, 124-125
- Lentiviruses, genomic organization of, 204-205
- LeVeen shunt, in disseminated intravascular coagulation treatment, 735
- Ligase chain reaction, in HIV detection, 262-263, 337
- Limited service laboratory testing, definition of, 455

- Linearity checks, in alternate-site testing, 594
- Liver, peritoneovenous shunt surgery involving, coagulopathies in, 776
- resection of, coagulopathies in, 776
- transplantation of, coagulopathies in, 774-776
- Liver disease, coagulopathies of, 769-780
- in cirrhosis, 771-773
- in mild disorders, 770-771
- in moderate disorders, 770-771
- in severe disorders, 770-771
- in surgical situations, 774-777
- vitamin K deficiency and, 773-774
- disseminated intravascular coagulation in, 733
- LKB instruments, for coagulation evaluation, 725
- Local area network, for laboratory information communication, 565-566
- Long terminal repeat, of HIV, 204, 208-210, 243-244
- Lumi-Aggregometer, for platelet function evaluation, 721
- Lung, hyaline microthrombi in, in disseminated intravascular coagulation, 741
- Lupus anticoagulants, laboratory assessment of, 795-801
- Lymphocytes, T. See *T lymphocytes*.
- Lymphoid tissue, HIV in, 341
- Lysis-centrifugation system, for blood cultures, 142-144
- in anaerobic bacteremia, 112-113
- in brucellosis, 122
- in pediatric patients, 24
- Lysostaphin test, for microorganism identification, in blood cultures, 184-185
- Macrophages, alveolar, in HIV-specific cytotoxic T lymphocyte detection, 272-273
- Maintenance, instrument, in alternate-site testing, 595-596
- Major histocompatibility complex, HIV infection effects on, 226-228
- Malassezia*, blood culture of, 24-25, 92-93
- Malignancy, blood-borne infection in, 32
- disseminated intravascular coagulation in, 733
- Manchester comparative reagent, in oral anticoagulation monitoring, 814
- Manual, policy and procedure, for alternate-site testing, 578-582, 598
- maintenance instructions in, 596
- safety policy in, 596-597
- MDA instrument, for coagulation evaluation, 719
- Media. See *Culture media*.
- Medical Laboratory Automation instruments, for coagulation evaluation, 712, 719
- Membrane glycoproteins, platelet, 687-688
- Meritec test, for rapid microbial identification, 188
- 12-Methoxydodecanoic acid, in HIV infection, 377
- Micro-ID system, for rapid microbial identification, 186-187
- MicroScan system, for antibiotic susceptibility testing, 176
- for blood cultures, 165-166
- Microscopy, in bacteremia, 26
- in blood culture. See *Blood cultures, direct microscopy of*
- physician-performed, 583-584
- Minerals, dietary, lead interaction with, 438
- "Minieparin" therapy, monitoring of, 832
- Mobile laboratory, 572
- Molecular markers, in disseminated intravascular coagulation diagnosis, 745-750
- Molecular recognition element, in biosensor, 460-461
- Mononuclear blood cells, peripheral. See *Peripheral blood mononuclear cells*.
- Multihospital systems, alternate-site testing in. See *Alternate-site testing, consolidation in multihospital systems*.
- Multiplex method, for polymerase chain reaction, in HIV infection, 319
- Murine leukemia virus, genes of, 204, 206
- Mycobacteremia, 99-105
- blood cultures in, 38-39, 101-102
- bone marrow cultures in, 102-103
- epidemiology of, 99-100
- in immunocompromised patients, 36, 38-39
- liver biopsy cultures in, 103
- microscopic detection of, 100-101
- Mycoplasma*, blood culture of, 125-126
- Myocardial infarction, disseminated intravascular coagulation in, 734
- Myristylation, in HIV replication, inhibitors of, 377-378
- Near-infrared spectroscopy, in blood gas analysis, 467-468
- Needles, switching of, in blood culture sampling, 62-63
- nef* gene and gene product, 205-206, 211-214
- cytotoxic T lymphocytes recognizing, 284-285
- Negative regulatory element, of HIV gene, 244-245

- Neomycin B, in HIV infection, 376  
 Neonates, lead poisoning in, 653  
 Nephropathy, lead, 652  
 Networks, for laboratory information communication, 563, 565-566  
 Neuropathy, in lead poisoning, 650-651  
 Neutralizing antibodies, in HIV infection, 264-266  
 Neutropenia, blood-borne infection in, 32  
 Nevirapine, HIV resistance to, 397, 399  
     as pathogenic factor, 408, 410  
     biochemical bases of, 404, 407  
     in combination therapy, 400  
 New Oxford method, for factor VIII inhibitor assessment, 805-806  
 NO donors, therapy with, monitoring of, 840  
*Nocardia*, blood culture of, 93  
 Nuclear factors, in HIV gene expression, 210, 244  
 Nucleic acid probes, in rapid microorganism detection, 191
- Obstetrical accidents, disseminated intravascular coagulation in, 731-732  
     treatment of, 753-754  
 Occupational exposure, to lead, 428, 430-431  
 Occupational Safety and Health Administration, lead exposure regulations of, 430-431  
 Office testing, physician, definition of, 455-456  
 Oligonucleotide(s), antisense, in HIV infection, 373-374  
 Oligonucleotide solution hybridization technique, in HIV detection, 317  
 Oncornaviruses, genomic organization of, 204-205  
 Oral anticoagulation, monitoring of, 813-823  
     historical background of, 813-815  
     international normalized ratios in, 817-821  
     reference preparations for, 815-817  
     thromboplastin calibration in, 817, 820  
 Organon Teknika instruments, for coagulation evaluation, 712, 725  
     for platelet function evaluation, 721, 729  
 Ortho Diagnostic Systems instruments, for coagulation evaluation, 712, 717  
     for platelet function evaluation, 721  
 Osteoporosis, in heparin therapy, 835  
 Oxygen, monitoring of, biosensors in, 466-468
- p24 antigen, assays for, 262-264, 307-308
- in drug resistance, 412  
 Paint, lead-containing, exposure to, 424-425, 427  
 Panic (critical) values, in alternate-site testing, 594  
 Paracoagulation tests, 737  
     for fibrinogen degradation products, 802  
 Paraproteins, heparinlike, laboratory assessment of, 802  
     inhibitors of, laboratory assessment of, 801-802  
 Partial thromboplastin time, dilute, in lupus anticoagulants, 798  
     in von Willebrand's disease, 789  
 Patient-centered units, 525-538  
     definition of, 526  
     laboratory for, 527, 573  
     cross-training in, 526, 528-529, 535-536  
     instrumentation for, 528  
     personnel performance in, 535-536  
     pilot project for, 527-535  
 Pediatric patients, blood cultures in, 17-30  
     anaerobic, 25  
     cost considerations in, 27  
     direct microscopy of, 26  
     incubation of, 25-26  
     laboratory issues in, 23-26  
     media for, 23-25  
     number of, 21-22  
     pathogens in, 17-20  
     specimen collection for, 20-23  
     timing of, 22  
     volume of, 22-23  
 HIV infection in, cytotoxic T lymphocyte function in, 285-286  
     polymerase chain reaction detection of, 323  
 HIV testing in, 262  
 lead exposure in, 427, 431-434  
 lead poisoning in, 651, 653  
     blood lead level interpretation in, 655-656  
     treatment of, 655  
 PEDS bottle system, for blood cultures, 24  
 Pentasaccharide therapy, monitoring of, 832  
 Pentosan polysulfate therapy, monitoring of, 832  
*Peptococcus*, blood culture of, 110  
 Peripheral blood, culture of, in catheter-related infections, 55  
 Peripheral blood mononuclear cells, cytotoxic T lymphocytes in, HIV-specific, 272-274, 278-279, 283  
 HIV burden in. See *Human immunodeficiency virus (type 1), burden of*  
 HIV DNA extraction from, 317  
 HIV expression in, in asymptomatic disease, 324-325

- nonuniform drug resistant quasispecies in, 394-395
- polymerase chain reaction detection of, 343. See also *In situ polymerase chain reaction*.
- vs. CD4 lymphocytes, 326
- HIV proviral sequences in, 240
- Peripheral neuropathy, in lead poisoning, 650-651
- Peritoneovenous shunt surgery, coagulopathies in, 776
- in disseminated intravascular coagulation treatment, 735
- Personnel, for alternate-site testing. See *Alternate-site testing, personnel for; Training*.
- Petechia, in disseminated intravascular coagulation, 739
- pathophysiology of, 679-680
- Phadebact test, for rapid microbial identification, 187-188
- Phenotypic assays, for HIV drug resistance, 410, 412-413
- Phenprocoumon, therapy with, monitoring of, 837
- Phosphatidylserine liposome APTT, in lupus anticoagulants, 799
- Physician office laboratory testing, definition of, 455-456
- Phytohemagglutinin-simulated mononuclear cells, in HIV-specific cytotoxic T lymphocyte detection, 273
- PITT system, in vitamin K antagonist therapy monitoring, 837
- Placenta, abruption of, disseminated intravascular coagulation in, 731
- lead measurement in, 658
- Plaque, atherosclerotic, in endothelial injury, 679
- Plasma proteins, in hemostasis, 688-699
- coagulation system, 689-692
- complement activation, 695-696
- fibrin, 691-692
- fibrinolytic system, 692-695
- inhibitor systems, 698-699
- kinin generation, 697-698
- modification of, in liver, 769-770
- synthesis of, in liver, 769-770
- thrombin, 691
- Plasmin, action of, 693-695
- in DIC, 737-738
- measurement of, in DIC, 747-748
- Plasmin-alpha-2-plasmin inhibitor complex, measurement of, in DIC, 748
- Plasminogen, action of, 693-694
- deficiency of, in cirrhosis, 772
- inhibitors of, action of, 694
- measurement of, in DIC, 747-748
- Plasminogen activator, action of, 694
- Platelet(s), activation of, 682-685
- aggregation of, collagen-induced, in anti-platelet therapy monitoring, 838-839
- in von Willebrand's disease, 788
- compounds released from, 682
- dysfunction of, in disseminated intravascular coagulation, 737-738, 748-749
- energy requirements of, 681-682
- function of, evaluation of, automated instruments for, 720-722
- in hemostasis, 681-688
- in liver disease, 773
- glycoproteins of, inhibitors of, therapeutic monitoring of, 839
- inhibitors of, 687
- in disseminated intravascular coagulation, 755, 758
- therapy with, monitoring of, 838-839
- interaction among, 685-686
- membrane glycoproteins of, 687-688
- morphology of, 681
- in disseminated intravascular coagulation, 740-741
- proteins of, 682
- transfusion of, in von Willebrand's disease, 791
- von Willebrand factor extracted from, assays on, 786-788
- Platelet count, in disseminated intravascular coagulation, 748-749
- in heparin therapy monitoring, 834-835
- low. See *Thrombocytopenia*.
- normal, 681
- Platelet factors, 682
- measurement of, in disseminated intravascular coagulation, 748-749
- Platelet neutralization procedure, in lupus anticoagulants, 798-799
- Platelet-induced thrombin generation time, in hirudin therapy monitoring, 836
- Plumbism. See *Lead poisoning*.
- Pneumoslide test, for rapid microbial identification, 188
- Point-of-care testing, definition of, 454-455
- Poisoning, lead. See *Lead poisoning*.
- pol gene and gene product, 204-206, 211
- Policy and procedure manual, for alternate-site testing, 578-582, 598
- maintenance instructions in, 596
- safety policy in, 596-597
- Polycythemia rubra vera, disseminated intravascular coagulation in, 733
- Polymerase chain reaction. See also *In situ polymerase chain reaction; Reverse transcriptase-polymerase chain reaction*.
- in HIV infection, 262-263, 313-333
- accuracy of, 318-319
- acridinium ester probe in, 317
- before seroconversion, 321-323
- carryover safeguards in, 316-317
- coamplification in, 321

- Polymerase chain reaction (*Continued*)  
 false results in, 317-318  
 historical background of, 314-316  
 hot-start method for, 315  
 in diagnosis, 316-319  
 in drug resistance detection, 410-411  
 in infants of HIV-positive mothers, 323  
 in pathogenesis studies, 324-327  
 in research, 324  
 in resolution of indeterminate serology, 323  
 in therapy monitoring, 327-328  
 multiplex method for, 319  
 nested primers in, 315-316, 320  
 Poisson statistics used in, 320  
 practicality of, 318-319  
 quantitation with, 319-321  
 sample preparation for, 317  
 sandwich system of, 317  
 specificity enhancement of, 314-316  
 in rapid microorganism detection, 191
- Polymerase-specific cytotoxic T lymphocytes, in HIV infection, 279, 283
- Potassium measurement, in portable analyzer, 486  
 preanalytical errors in, 545
- PPG StatPal blood gas tester, 487
- Pregnancy, disseminated intravascular coagulation in, 731-732  
 lead poisoning in, 439, 653  
 lupus anticoagulants in, 797
- Prekallikrein, in hemostasis, 697
- Procedure manual, for alternate-site testing, 578-582, 598  
 maintenance instructions in, 596  
 safety policy in, 596-597
- Professional organizations, position on alternate-site testing, 456-457
- Proficiency testing, in alternate-site testing, 482, 484, 595  
 in multihospital system, 503-504  
 survey on, 637-640
- Propionibacterium*, blood culture of, 109
- Prostaglandins, in platelet function, 686-687
- Prostheses, cardiovascular, disseminated intravascular coagulation from, 734-735
- Protamine sulfate test, for fibrinogen degradation products, 802  
 in disseminated intravascular coagulation, 743-744
- Protease inhibitors, in HIV infection, 378-379
- Protein(s), plasma. *See Plasma proteins.*
- Protein C, deficiency of, coumarin necrosis in, 837  
 in cirrhosis, 772
- in coagulation regulation, 698
- Protein S, in coagulation regulation, 698
- Proteinuria, in disseminated intravascular coagulation, 739
- Proteoglycans, in coagulation regulation, 701-702
- Prothrombin fragments, in coagulation regulation, 699  
 measurement of, in disseminated intravascular coagulation, 745
- Prothrombin time, in cirrhosis, 772  
 in disseminated intravascular coagulation, 742  
 in oral anticoagulation monitoring, 813-815  
 measurement of, automated instruments for, 710-715
- Proton-induced x-ray emission, in lead measurement, 661
- Pseudohypericin, in HIV infection, 372
- Pseudopods, platelet, 683-684
- Pulmonary disease, in HIV infection, cytotoxic T lymphocytes in, 286
- Pulse oximetry, 467
- Purpura, in disseminated intravascular coagulation, 739
- PYR test, for microorganism identification, in blood cultures, 186
- L-Pyrrolidonyl- $\beta$ -naphthylamide reaction, for microorganism identification, in blood cultures, 186
- Q-Probes Study, of College of American Pathologists, 475-480, 482, 484
- Quality assurance, in alternate-site testing, training for, 590-592  
 in bedside testing, 481-485
- Quality control, in alternate-site testing, 539-557, 633, 637  
 CLIA 1988 regulations and, 550-552  
 definition of, 541  
 financial aspects of, 541-542  
 for sophisticated instrumentation, 548-549  
 history of, 546  
 quality control samples in, 549  
 system checks in, 549  
 testing cycle and, 543-550  
 analytical phase of, 546-549  
 post-analytical phase of, 549-550  
 preanalytical phase of, 544-545  
 training for, 590-594  
 validity checks in, 549
- in lead measurement, 664
- of coagulation evaluation automated instrumentation, 725-726
- Rabbit brain neutralization test, in lupus anticoagulants, 799

- Radial immunodiffusion assay, for coagulation evaluation, 723-724
- Radioimmunoassay, for coagulation evaluation, 723, 725
- for fibrinopeptides, in disseminated intravascular coagulation, 747
- Radioimmunoprecipitation assay, for HIV antibodies, 258-259
- Radiology, in bone lead assessment, 663
- Receptor interference, in HIV infection, 213
- Regulations, for alternate-site testing, 480, 583-585. See also *Clinical Laboratory Improvement Amendments*.
- local differences in, 585
- personnel requirements in, 575
- Reproductive system, lead poisoning effects on, 653
- Reptilase test, in disseminated intravascular coagulation, 743
- Resistance, to antiretroviral drugs. See *Antiretroviral drugs, HIV resistance to*.
- Respiratory distress, in disseminated intravascular coagulation, 741
- Respiratory therapy, testing in, 627
- perceived performance of, 642
- proficiency, 639
- revenues from, 635
- Restriction fragment length polymorphisms, in von Willebrand's disease, 789-790
- Results reporting, time of, for biosensors, 462-463
- Retained fetus syndrome, disseminated intravascular coagulation in, 731
- Retroviruses. See also *Human immunodeficiency virus (type 1)*.
- genomic organization of, 204-205
- viral latency and, 242-246
- life cycle of, 203-204
- rev* gene and gene product, 205-206, 211, 243
- inhibitors of, in HIV infection, 376
- Reverse transcriptase, cells expressing, cytotoxic T lymphocytes recognizing, 279, 283
- structure of, drug resistance and, 404-407
- Reverse transcriptase-polymerase chain reaction, in HIV infection, 335-349
- clinical applications of, 340-342
- competitive template for, 339-340
- external controls for, 339
- in cells, 342-343
- in plasma, 343-346
- precision of, 337-338
- priming in, 336
- quantitation with, 339-340
- sample handling for, 338-339
- rgp160, in HIV vaccine preparation, 291
- Ribozymes, in HIV infection, 374-375
- Ristocetin co-factor activity, assay for, 782, 785
- Ristocetin-induced platelet aggregation reaction, 788
- RNA, of HIV, antisense, 374
- measurement of, 307-308
- Ro 5-3335 (benzodiazepine), in HIV infection, 375-376
- Ro 31-8959 (protease inhibitor), in HIV infection, 378-379
- Russell viper venom time, dilute, in lupus anticoagulants, 798-799
- Safety, in alternate-site testing, training for, 596-597
- in blood culture processing, 127
- in blood culture sample collection, 61
- Salmonella typhi*, rapid detection of, in blood, 191
- Sandwich technique, in polymerase chain reaction, in HIV detection, 317
- Sarcoma, Kaposi's, interferon alpha for, 379-380
- Satellite laboratory, 571-572
- Schistocytes, in disseminated intravascular coagulation, 740
- Scoring system, for disseminated intravascular coagulation, in diagnosis, 750-752
- in treatment, 758-759
- Semen, HIV in, 341
- Sensors. See *Biosensors*.
- Sepsis, definition of, 2-3
- Septicemia, definition of, 2-3
- disseminated intravascular coagulation in, 732-733
- treatment of, 754
- Septi-Chek system, for blood cultures, 137-138
- in anaerobic bacteraemia, 112
- in fungemia, 85-87, 90-91
- in pediatric patients, 23
- Serologic assays, in HIV infection, 257-269
- for anti-HIV antibodies, confirmatory, 261-262
- screening, 258-260
- for neutralizing antibodies, 264-266
- for p24 antigen, 262
- for type 2 virus antibodies, 261-262
- for viral DNA/RNA, 262-263
- for virions, 262-263
- prognostic value of, 263-264
- Serostat tests, for rapid microbial identification, 188-189

- Shunt, peritoneovenous, in disseminated intravascular coagulation treatment, 735  
 installation of, coagulopathies in, 776
- Sienco instruments, for platelet function evaluation, 721
- Signal broth displacement blood culture system, 139-140
- Skin, antisepsis for, in blood culture sample collection, 60-61  
 bacterial culture from, in catheter-related infections, 54  
 necrosis of, from vitamin K antagonists, 837
- Sodium, determination of, in portable analyzer, 486
- Sodium amylosulfate, as anticoagulant, in blood cultures, 75
- Sodium polyanetholsulfonate, as anticoagulant, in blood cultures, 74-75
- Soft tissue, lead measurement in, 658  
 sample collection for, 660
- Soil, lead content of, 425-426
- Sonoclot instrument, for coagulation evaluation, 714
- Specimens, collection of, for blood culture. See under *Blood cultures*.  
 size of, for biosensor use, 461-462
- Spectrophotometer, in chromogenic assay, of coagulation, 717
- Spectroscopy, near-infrared, in blood gas analysis, 467-468
- Spumaviruses, genomic organization of, 204-205
- 3SR reaction, in HIV detection, 336
- STA instrument, for coagulation evaluation, 719-720
- Standard deviation, in quality control, 546-547
- Staphaurex test, for rapid microbial identification, 189
- Staphylococcus aureus*, rapid detection of, in blood, 184-185, 188-189
- Staphyloslide test, for rapid microbial identification, 189
- Stool, HIV in, 340-341
- Streplslide test, for rapid microbial identification, 188
- Streptex test, for rapid microbial identification, 188
- Streptococci, vitamin B<sub>6</sub>-dependent, blood culture of, 127
- Streptococcus pneumoniae*, rapid detection of, in blood, 185-186, 188
- Streptococcus pyogenes*, rapid detection of, in blood, 186
- Subcultures, of blood, 76-78  
 in immunocompromised patients, 41
- Superantigen effect, in HIV infection, T-lymphocyte depletion and, 228
- Suramin, anticoagulant effect of, 803
- Surgery, testing during, 627  
 perceived performance of, 642
- personnel for, 632
- proficiency, 638
- revenues from, 635
- Susceptibility testing, antibiotic, 171-179
- Sweat, HIV in, 341
- Syncytia formation, by T lymphocytes, in HIV infection, 232, 304-305, 408
- Systemic lupus erythematosus, lupus anticoagulants in, 797-798
- T lymphocytes, CD4, analogs of, antiretroviral activity of, 370-371
- HeLa cell plaque reduction assay, in HIV drug resistance monitoring, 413
- HIV infection impact on, 205, 207-208, 221-228
- anergy, 229
- antiretroviral drugs affecting, 370-371
- apoptosis, 229-230
- direct cytopathy, 225
- endocytosis, 213-214
- immunomodulation, 225-228
- in active disease, 231-232
- in acute disease, 221-223
- in quiescent disease, 223, 225-228
- kinetics of depletion, 232-234
- mechanisms of, 222
- Nef protein and, 212-214
- polymerase chain reaction studies of, 324-325, 342-343
- precursor cell loss, 230-231
- signaling defects, 228-230
- superantigen effects, 228
- syncytia formation, 232, 304-305, 408
- time course of, 222
- virus burden in, 302-305
- recombinant soluble forms of, antiretroviral activity of, 370-371
- CD8, HIV infection impact on, 223
- cytotoxic, in HIV infection, 271-299
- activity decline in, 289
- cloned, 273-274, 290
- cytotoxicity assay of, 277
- detection of, 272-277
- envelope-specific, 283-284
- epitopes recognized by, 277-285
- functions of, 285-290
- gag-specific, 278-279
- in pediatric patients, 285-286
- nef-specific, 284-285
- pathogenetic role of, 286-287
- polymerase-specific, 279, 283

- protective role of, 285-286  
 target cell recognition in, 274-277  
 vaccine-induced, 290-292  
 viral escape from, 287-290
- TAR elements, of HIV gene, 208, 210  
 in gene therapy, 381
- Target cells, for cytotoxic T-lymphocyte detection, 274-277
- TAS Analyzer, for coagulation evaluation, 715
- tat* gene and gene product, 205-206, 211, 243  
 inhibitors of, in HIV infection, 375-376
- Teeth, lead measurement in, 657, 660
- Telangiectasia, hereditary hemorrhagic, disseminated intravascular coagulation in, 734
- Temperature, for blood culture incubation, 73-74
- Template bleeding time, in von Willebrand's disease, 789
- Terminal subcultures, of blood, 76-78  
 in immunocompromised patients, 41
- Thermonuclease test, for microorganism identification, in blood cultures, 185
- Thrombin, action of, in disseminated intravascular coagulation, 738  
 formation of, 691  
 inhibitors of, therapy with, monitoring of, 835-836  
 measurement of, chromogenic assay in, 716-717
- Thrombin time, in disseminated intravascular coagulation, 743  
 in heparin therapy monitoring, 827, 829
- Thrombin-antithrombin complex, measurement of, in disseminated intravascular coagulation, 745
- Thrombin-inhibiting peptides, therapy with, monitoring of, 836
- Thrombocytopenia, from lupus anticoagulants, 798  
 heparin-induced, 834-835  
 in disseminated intravascular coagulation, 735, 737-738, 740, 748-749  
 in liver disease, 771, 773  
 in von Willebrand's disease, 788
- Thromboelastograph, for coagulation evaluation, 714
- Thromboplastin, standardized preparations of, for oral anticoagulation monitoring, 814-817
- Thromboplastin time, in vitamin K antagonist therapy monitoring, 837
- Thrombosis, from lupus anticoagulants, 797-798  
 in cardiovascular prostheses, 735  
 in disseminated intravascular coagulation, 730, 738  
 in diagnosis, 739
- morbidity and mortality from, 741-742  
 morphology of, 740-741  
 treatment of, 754-755
- of hepatic artery, in liver transplantation, 776
- Thromboxane(s), in platelet function, 686-687
- Thromboxane receptor antagonists, therapy with, monitoring of, 839
- Thromboxane synthetase inhibitors, therapy with, monitoring of, 839
- Tiacytidine (3TC), HIV resistance to, 396, 398  
 biochemical bases of, 406
- TIBO compounds, HIV resistance to, 397, 399
- Ticlopidine therapy, monitoring of, 838-839
- Tissue thromboplastin inhibition test, in lupus anticoagulants, 799
- Topoisomerase inhibitors, in HIV infection, 372
- Toxins, conjugated to CD4 cells, antiretroviral activity of, 371
- Training, for alternate-site testing, 482, 578-582, 588-590  
 aids for, 597-598  
 concepts of, 598-599  
 continuing education in, 599-602  
 director for, 582  
 elements of, 601-602  
 ethos in, 589  
 in patient-centered units, 526, 528-529, 535-536  
 instrument maintenance, 595-596  
 laboratory principles, 590-599  
 quality assurance, 590-592  
 quality control, 592-594  
 safety principles, 596-597
- Tranexamic acid, in disseminated intravascular coagulation, 757
- Transcription-based amplification system, in HIV detection, 336-337
- Transcutaneous biosensors, 466-467
- Transdominant mutant proteins, expression of, in gene therapy for HIV infection, 381
- Transducer, in biosensor, 460-461
- Transfusion therapy, in disseminated intravascular coagulation, 756
- Transplantation, immunosuppression in, blood-borne infection in, 32-33  
 liver, coagulopathies in, 774-776
- Triage device, for urine screening, 487
- TSAO compounds, HIV resistance to, 397, 399
- Tuberculosis, disseminated. See *Mycobacteremia*.
- Tumor necrosis factor, from cytotoxic T lymphocytes, in HIV infection
- pathogenesis, 287

- Universal precautions, in blood culture sample collection, 61
- Untranslated binding protein, in HIV gene transcription, 245
- Upstream suppressor sequence, of HIV gene, 245
- Uracil N-glycosylase, in polymerase chain reaction, in HIV detection, 316
- Urea determination, in portable analyzer, 486
- Urine, drug screening of, portable device for, 487
- lead measurement in, 656
- methods for, 662
- sample collection for, 659-660
- Vaccines, for HIV infection, cytotoxic T lymphocytes induced by, 290-292
- Vacutainer system, for blood cultures, 138
- Varicella, disseminated intravascular coagulation in, 733
- Varices, esophageal, embolization of, coagulopathies in, 776-777
- Vascular system, endothelium of, in
- hemostasis, 678-680
- injury of, disseminated intravascular coagulation in, 735
- fragility of, petechiae in, 679-680
- function of, in hemostasis, 678-680
- morphology of, 678
- permeability of, petechiae in, 679
- Vasoconstriction, regulation of, 680
- Vasospastic disease, disseminated intravascular coagulation in, 734
- Venipuncture, in blood culture sampling, vs. catheter specimens, 61-62
- Veterans Affairs medical care system, alternate-site testing in. See *Alternate-site testing, consolidation in multihospital systems*.
- vif gene and gene product, 205-206, 211, 214-215
- Viral cultures, blood, in
- immunocompromised patients, 39-40
- in HIV drug resistance monitoring, 412-413
- Viral infections, disseminated intravascular coagulation in, 733
- Viremia, in HIV infection, vs. disease progression, 303-304
- Vitamin B<sub>6</sub>-dependent streptococci, blood culture of, 127
- Vitamin D metabolism, lead poisoning and, 438
- Vitamin K, antagonists of, side effects of, 837
- therapy with, monitoring of, 837
- deficiency of, in liver disease, coagulopathies in, 773-774
- in coagulation, 691
- requirements of, in coagulation protein modification, 769-770
- Vitek system, for antibiotic susceptibility testing, 176
- for rapid microbial identification, 186-187
- von Willebrand factor, antigen of, assay for, 782, 785-786
- assays for, 782, 785-788
- deficiency of, 783
- levels of, factors affecting, 784-785
- multimers of, assay for, 782, 786
- structures of, 784
- qualitative abnormalities of, 783-784
- replacement of, in von Willebrand's disease, 791
- structure of, 784
- von Willebrand's disease, 781-794
- acquired, diagnosis of, 790-791
- laboratory assessment of, 808
- assays in, 782, 785-788
- classification of, 783-784
- clinical presentation of, 782-783
- definitions in, 782
- diagnosis of, acquired, 790-791
- problems in, 791
- genetic studies in, 789-790
- laboratory tests for, 784-789
- nomenclature in, 782
- platelet-type, 788
- prenatal diagnosis of, 790
- prevalence of, 781
- treatment of, 791
- undiagnosed, 781
- variants of, diagnostic problems with, 791
- vpr gene and gene product, 205-206, 211, 215
- vpu gene and gene product, 205-206, 211, 215-216
- vpx gene, 205-206
- Waived test category, regulations on, 551, 583-584
- Warfarin therapy, monitoring of, 837. See also *Oral anticoagulation, monitoring of*.
- Water, drinking, lead content of, 426-427
- Western blot test, in HIV infection, 261-262
- indeterminate, polymerase chain reaction resolution of, 323
- White clot syndrome, in heparin therapy, 834-835
- Whole blood clotting time, in heparin therapy monitoring, 827
- Wide area network, for laboratory information communication, 565-566

World Health Organization, in oral anticoagulation monitoring standardization, 814-821

X-ray fluorescence technique, in lead measurement, 662-663

Zalcitabine (ddC), HIV resistance to, 396, 398-399

biochemical bases of, 406-407  
in combination therapy, 400

Zidovudine (AZT), HIV resistance to, as pathogenic factor, 408-409

biochemical bases of, 404, 406-407

crossresistance of, 398

genetic factors in, 395-396, 398

in combination therapy, 400-404

laboratory monitoring of, 410-413

polymerase chain reaction studies of, 324

in HIV infection, efficacy of, monitoring of, 413-414

interferon alpha with, 379-380

monitoring of, polymerase chain reaction in, 327, 345-346

virus burden response to, 305-308  
with *N*-butyl deoxyoxojoirimicin, 377

Zinc protoporphyrin, measurement of, 661-662

vs. free erythrocyte protoporphyrin, 654